CAS 1256580-46-7: Alectinib
Description:Alectinib is a small molecule drug primarily used in the treatment of non-small cell lung cancer (NSCLC) that is positive for anaplastic lymphoma kinase (ALK) gene rearrangements. It functions as a selective inhibitor of ALK, disrupting the signaling pathways that promote tumor growth and survival. Alectinib is characterized by its high potency and specificity for ALK, which helps minimize off-target effects and enhances its therapeutic efficacy. The compound is typically administered orally and has a favorable pharmacokinetic profile, including good absorption and a long half-life, allowing for once or twice daily dosing. Its chemical structure includes a bicyclic core, contributing to its ability to penetrate the blood-brain barrier, making it effective against brain metastases associated with ALK-positive NSCLC. Common side effects may include fatigue, constipation, and liver enzyme elevations, necessitating monitoring during treatment. Overall, Alectinib represents a significant advancement in targeted cancer therapy, offering improved outcomes for patients with specific genetic profiles.
Formula:C30H34N4O2
InChI:InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3
InChI key:InChIKey=KDGFLJKFZUIJMX-UHFFFAOYSA-N
SMILES:N#CC=1C=CC2=C(C1)NC3=C2C(=O)C=4C=C(C(=CC4C3(C)C)N5CCC(N6CCOCC6)CC5)CC
- Synonyms:
- 5H-Benzo[b]carbazole-3-carbonitrile, 9-ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-
- 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile
- Af 802
- Alecensa free base
- Ch 5424802
- Ch 542480210
- Rg 7853
- Rg7853